Referencias

  1. Organización Mundial de la Salud. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: tratamiento. Tratamiento de la tuberculosis farmacosensible. Ginebra: OMS; [de próxima publicación en español].
  2. Organización Mundial de la Salud. WHO operational handbook on tuberculosis Module 4: Treatment – tuberculosis care and support. Ginebra: OMS; 2022.
  3. Organización Mundial de la Salud. The End TB Strategy (WHO/HTM/TB/2015.19). Ginebra: OMS; 2015. Disponible en: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19.
  4. Organización Mundial de la Salud. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – rapid diagnostics for tuberculosis detection. Ginebra: OMS; 2021. Disponible en: https://apps.who.int/iris/handle/10665/342331.
  5. Organización Mundial de la Salud. Global tuberculosis report 2021. Ginebra: OMS; 2021. Disponible en: https://www.who.int/publications/i/item/9789240037021.
  6. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779-87. Disponible en: https://www.researchgate.net/publication/324677816_Prevalence_of_drug-resistant_tuberculosis_and_imputed_burden_in_South_Africa_a_national_and_sub-national_cross-sectional_survey.
  7. Kayomo MK, Mbula VN, Aloni M, André E, Rigouts L, Boutachkourt F et al. Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo. Sci Rep. 2020;10(1):10786. Disponible en: https://www.nature.com/articles/s41598-020-67479-4.
  8. Lim DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, Cabibbe AM, Zignol M et al. Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. Eur Respir J. 2018;51(3):1702571. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29496754/.
  9. Mesfin AB, Araia ZZ, Beyene HN, Mebrahtu AH, Suud NN, Berhane YM et al. First molecular-based anti-TB drug resistance survey in Eritrea. Int J Tuberc Lung Dis. 2021;25(1):43-51. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33384044/.
  10. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185-92. Disponible en: https://www.em-consulte.com/article/1081233/population-based-resistance-of-mycobacterium-tuber.
  11. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974034/.
  12. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20101802/.
  13. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid- resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369-72. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21810750/.
  14. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis. 2012;16(6):812-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22507372/.
  15. Namugenyi J, Musaazi J, Katamba A, Kalyango J, Sendaula E, Kambugu A et al. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. BMC Infect Dis. 2021;21(1):513. Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06220-6.
  16. Step Up for TB 2020. Ginebra: Alianza Alto a la Tuberculosis; 2020. Disponible en: https://www.stoptb.org/advocate-to-endtb/step-tb-2020.
  17. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C et al. Market penetration of Xpert MTB/ RIF in high tuberculosis burden countries: a trend analysis from 2014 - 2016. Gates Open Res. 2018;2:35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139378/.
  18. Organización Panamericana de la Salud. Manual operativo de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: OPS; 2020. Disponible en: https://iris.paho.org/handle/10665.2/55997.
  19. Organización Mundial de la Salud. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2.ª edición. Ginebra: OMS; 2014. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf.
  20. Organización Panamericana de la Salud. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 5: Manejo de la tuberculosis en la población infantil y adolescente Washington, D. C.: OPS [de próxima publicación en español].
  21. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-79. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10529902/.
  22. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug- resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20797644/.
  23. Organización Mundial de la Salud. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Ginebra: OMS; 2016. Disponible en: https://apps.who.int/iris/handle/10665/208825.
  24. Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111-5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794061/.
  25. Alffenaar J-WC, Akkerman OW, Bothamley G. Monitoring during and after treatment. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:308-25. Disponible en: https://doi.org/10.1183/2312508X.10022217.
  26. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. Four-month moxifloxacin- based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577-87. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1407426.
  27. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588-98. Disponible en: https://pubmed. ncbi.nlm.nih.gov/25337748/.
  28. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599-608. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1314210.
  29. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705-18. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33951360/.
  30. Organización Panamericana de la Salud. Manual operativo de la OMS sobre la tuberculosis. Módulo 5: Manejo de la tuberculosis en la población infantil y adolescente. Washington, D. C.: OPS [de próxima publicación en español].
  31. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(10):911-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35263517/.
  32. Organización Panamericana de la Salud. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 1: Prevención. Tratamiento preventivo de la tuberculosis. Washington, D. C.: OPS; 2020. Disponible en: https://iris.paho.org/handle/10665.2/52261.
  33. Organización Mundial de la Salud. Guideline: updates on the management of severe acute malnutrition in infants and children. Ginebra: OMS; 2016 (https://apps.who.int/iris/bitstream/handle/10665/95584/9789241506328_ eng.pdf?sequence=1&isAllowed=y).
  34. Organización Panamericana de la Salud. Definición de la OMS de caso de infección por el VIH a efectos de vigilancia y revisión de la estadificación clínica y de la clasificación inmunológica de la enfermedad relacionada con el VIH en adultos y niños. Washington D. C.: Organización Panamericana de la Salud; 2009 (https://www.paho.org/hq/dmdocuments/2009/DEFINICION_ESTADIFICACION2.pdf ).
  35. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD et al. Treatment of active tuberculosis in HIV- coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288-99 (https://pubmed.ncbi.nlm.nih.gov/20353364/).
  36. Organización Mundial de la Salud. Guidelines for treatment of drug-susceptible tuberculosis and patient care, actualización del 2017. Ginebra: Organización Mundial de la Salud; 2017. Disponible en: https://apps.who.int/iris/handle/10665/255052.
  37. Organización Mundial de la Salud. Política de la OMS sobre actividades de colaboración TB/VIH: Guías para programas nacionales y otros interesados directos (directrices de la OMS aprobadas por el Comité de Examen de Directrices). Ginebra: OMS; 2012. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/44838/9789243503004_spa.pdf?sequence=1&isAllowed=y.
  38. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915-25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30428290/.
  39. Holden IK, Lillebaek T, Andersen PH, Bjerrum S, Wejse C, Johansen IS. Extrapulmonary tuberculosis in Denmark from 2009 to 2014; characteristics and predictors for treatment outcome. Open Forum Infect Dis. 2019;6(10):ofz388. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31660351/.
  40. Bruchfeld J, Forsman LD, Fröberg G, Niward K. Extrapulmonary tuberculosis. En: Migliori GB & Raviglione MC (eds.), Essential tuberculosis. Suiza: Springer, Cham; 2021:259-66. Disponible en: https://doi.org/10.1007/978-3-030-66703-0_29.
  41. Fontanilla J-M, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis. 2011;53(6):555-62. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21865192/.
  42. Rieder HL. Epidemiological basis of tuberculosis control. París: International Union Against Tuberculosis and Lung Disease; 1999. Disponible en: https://tbrieder.org/publications/books_english/epidemiology_en.pdf.
  43. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27516382/.
  44. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (National Institute for Health and Clinical Excellence: Guidance). Londres: National Collaborating Centre for Chronic Conditions; 2006. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK45802/.
  45. Treatment of tuberculosis. Morbidity and Mortality Weekly Report, American Thoracic Society, CDC and Infectious Diseases Society of America; 2003. Disponible en: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
  46. Organización Mundial de la Salud. Treatment of tuberculosis: guidelines for national programmes, 4.a edición. Ginebra: OMS; 2010. Disponible en: https://apps.who.int/iris/handle/10665/44165.
  47. Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/8868018/.
  48. Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Int J Tuberc Lung Dis. 1994;75(3):203-7. Disponible en: https://www.sciencedirect. com/science/article/abs/pii/0962847994900094.
  49. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol. 2009;103(7):625-34. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19825284/.
  50. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9024451/.
  51. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741-51. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15496623/.
  52. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Intervenciones para el tratamiento de la pericarditis tuberculosa. Cochrane Database Syst Rev. 2002;(4):CD000526. Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000526/full/es.
  53. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223-37. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23369413/.
  54. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121-30. Disponible en: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1407380.
  55. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183-8 (https://pubmed.ncbi.nlm.nih.gov/10908256/).
  56. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J S Afr. 2006;17(5):233-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17117227/.
  57. Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14443596/.
  58. Strang JI, Kakaza HH, Gibson DG, Allen BW, Mitchison DA, Evans DJ et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2(8614):759-64. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2901610/.
  59. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2891992/.
  60. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261-84. Disponible en: https://researchonline.jcu.edu.au/54740/.
  61. Magis-Escurra C, Carvalho ACC, Kritski AL, Girardi E. Comorbidities. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:276- 90. Disponible en: https://doi.org/10.1183/2312508X.10022017.
  62. Tiberi S, Pontali E, Tadolini M, D’Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019;80S:S68-S72. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30690212/.
  63. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care. 2012;185(7):779-84. Disponible en: https://www.atsjournals.org/doi/10.1164/rccm.201106-1083OC.
  64. Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E et al. Prevalence and clinical characteristics of pulmonary tuberculosis among pregnant and post-partum women in Mozambique. 2022.
  65. Jana N, Barik S, Arora N, Singh AK. Tuberculosis in pregnancy: the challenges for South Asian countries. J Obstet Gynaecol Res. 2012;38(9):1125-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22563776/.
  66. LaCourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of adverse infant outcomes associated with maternal tuberculosis in a low burden setting: a population-based retrospective cohort study. Infect Dis Obstet Gynecol. 2016;2016:6413713. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771913/.
  67. Chang C-W, Wu PW, Yeh C-H, Wong K-S, Wang C-J, Chang C-C. Congenital tuberculosis: case report and review of the literature. Paediatr Int Child Health. 2018;38(3):216-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28421876/.
  68. Sulis G, Gnanou S, Roggi A, Konseimbo A, Giorgetti PF, Castelli F et al. Active tuberculosis case finding among pregnant women: a pilot project in Burkina Faso. Int J Tuberc Lung Dis. 2016;20(10):1306-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27725039/.
  69. Caminero JA, Scardigli A, van der Werf T, Tadolini M. Treatment of drug-susceptible and drug-resistant tuberculosis. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:152-78. Disponible en: https://research.rug.nl/en/publications/ treatment-of-drug-susceptible-and-drug-resistant-tuberculosis.
  70. Caminero JA, Lasserra P, Piubello A. Adverse anti-tuberculosis drug events and their management. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:205-27. Disponible en: https://doi.org/10.1183/2312508X.10021617.
  71. Schaaf HS, Marais BJ, Carvalho I. Challenges in childhood tuberculosis. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:234-62. Disponible en: https://www.ers-education.org/lr/show-details/?idP=214582.
  72. Repossi A, Bothamley G. Tuberculosis in pregnancy and the elderly. En: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (monografía de la ERS). Sheffield: European Respiratory Society; 2018:263-75. Disponible en: https://www.ers-education.org/lr/show-details/?idP=214583.
  73. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93-e142. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31729908/.
  74. Kawatsu L, Yoshiyama T, Kato S. Tuberculosis in the elderly. En: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Suiza: Springer; 2021:253-8. Disponible en: https://doi.org/10.1007/978-3-030-66703-0_28.
  75. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med. 1985;312(23):1483-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/3990748/.
  76. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. Morbidity and Mortality Weekly Report, Estados Unidos: CDC; 1990.
  77. Global burden of disease [sitio web]. Institute for Health Metrics Evaluation; 2019. Disponible en: https://www.healthdata.org/gbd/2019.
  78. Department of Epidemiology and Clinical Research [sitio web]. Tokio: The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association; 2022. Disponible en: https://jata.or.jp/english/decr.html.
  79. Lin H-S, Cheng C-W, Lin M-S, Chou Y-L, Chang P-J, Lin J-C et al. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. Clin Interv Aging. 2016;11:299-306. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795580/.
  80. Yoshiyama T. Tuberculosis treatment for patients more than 80 years old. Kekkaku: [Tuberculosis]. 2017;92(7):485-91. Disponible en: https://www.researchgate.net/publication/320857126_Tuberculosis_ treatment_for_ patients_more_than_eighty_years_old.
  81. Igari H, Imasawa T, Noguchi N, Nagayoshi M, Mizuno S, Ishikawa S et al. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis. J Infect Chemother. 2015;21(8):559-63. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26048063/.
  82. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet. 2005;44(3):221-35. Disponible en: https://pubmed.ncbi. nlm.nih.gov/15762766/.
  83. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173-84. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17630041/.
  84. Matsumoto K, Komukai J, Kasai S, Hirota S, Koda S, Terakawa K et al. [Evaluation of risk factors for failed/ defaulted on treatment outcomes of pulmonary tuberculosis in Osaka City]. Kekkaku: [Tuberculosis]. 2014;89(6):593-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25095644/.
  85. Palmero D, Mendoza A. Clinical and programmatic aspects of kidney and liver failure and its impact on tuberculosis. En: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Suiza: Springer; 2021:267- 74. Disponible en: https://doi.org/10.1007/978-3-030-66703-0_29.
  86. Organización Mundial de la Salud. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Ginebra: OMS; 2015. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf.
  87. Sonika U, Kar P. Tuberculosis and liver disease: management issues. Trop Gastroenterol. 2012;33(2):102-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23025055/.
  88. Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012;2(3):260-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25755442/.
  89. Bosch A, Valour F, Dumitrescu O, Dumortier J, Radenne S, Pages-Ecochard M et al. A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area. Med Mal Infect. 2019;49(4):231-40. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30591271/.
  90. Caminero JA, Migliori GB. Rationale for anti-tuberculosis chemotherapy. En: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Suiza: Springer; 2021:109-20. Disponible en: https://doi.org/10.1007/ 978-3-030-66703-0_12.
  91. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15-S25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32032752/.
  92. Organización Panamericana de la Salud. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D. C.: OPS; 2022. Disponible en: https://iris.paho.org/handle/10665.2/56062.
  93. Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016;48(4):1160-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27587552/.
  94. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32636299/.
  95. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15971391/.
  96. Organización Panamericana de la Salud. Directrices para el manejo programático de la tuberculosis drogorresistente, actualización del 2011. Washington D. C.: OPS; 2011. Disponible en: https://www.paho. org/hq/dmdocuments/2013/Guias-Tecnicas-MPTD-2011-Spanish-2011.pdf.
  97. Organización Mundial de la Salud. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17-19 November 2020. Ginebra: OMS; 2021. Disponible en: https://apps.who.int/iris/handle/10665/340284.
  98. Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804. Disponible en: https://pubmed. ncbi.nlm.nih.gov/34413124/.
  99. Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M et al. What is behind programmatic treatment outcome definitions for tuberculosis? Eur Clin Respir J. 2020;56(1):2001751. Disponible en: https://erj.ersjournals.com/content/56/1/2001751.
  100. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797-813. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34615577/.

Book navigation